EnBiotix Raises $11M to Develop Antibiotics for Lung Infections

EnBiotix Raises $11M to Develop Antibiotics for Lung Infections

315134

EnBiotix Raises $11M to Develop Antibiotics for Lung Infections

EnBiotix has raised $11 million in financing that will help fund clinical testing of ColiFin (inhaled colistimethate sodium) and murepavadin, two antibiotics that may be useful for controlling lung infections in people with cystic fibrosis (CF). Some of the funding was from the Cystic Fibrosis Foundation, which joined the investment mainly to fund long-term safety studies of ColiFin, an inhaled antibiotic that has been approved in Europe for more than a decade as a treatment…

You must be logged in to read/download the full post.